

DIAGNOSTIC & THERAPEUTIC STUDY

● Prostate Cancer Clinical Trial (PSMA-Targeted Diagnostic & Therapeutic Study)

- **Eligibility:** Individuals with advanced or metastatic prostate cancer
- **Focus:** Precision imaging and investigational PSMA-targeted radiopharmaceuticals
- **Purpose:** Evaluate diagnostic accuracy and potential outcomes of targeted radioligand agents
- **Potential Benefit:** Early access to study-related evaluations and investigational agents

BENEFITS OF PARTICIPATION:

- 1 Access to advanced imaging and investigational agents.
- 2 Multidisciplinary care led by experienced nuclear medicine specialists.
- 3 Opportunity to contribute to ongoing cancer research under expert supervision.

WHY CHOOSE US?

Excel Diagnostics & Nuclear Oncology Center in Houston, Texas, is offering access to cutting-edge clinical trials for cancer patients. These trials focus on advanced diagnostic and therapeutic approaches to improve outcomes.

- 1 **Prostate Cancer Trial:** Investigating PSMA-targeted imaging and therapies.
- 2 **Brain Tumor Studies:** Exploring novel radiolabeled agents for glioblastoma.
- 3 **Solid Tumor Research:** Combining imaging with targeted radiotherapy for various cancers.
- 4 **Targeted Alpha Therapy:** Focused on advanced NET tumors and prostate cancer. This drug has received break through designation by FDA



Excel Diagnostics & Nuclear Oncology Center

ADVANCING
CANCER
RESEARCH
OPPORTUNITIES

DIAGNOSTICS

1 Brain Tumor Clinical Trial (Glioblastoma - GBM)

- **Eligibility:** Adults with newly diagnosed or recurrent GBM
- **Focus:** Investigational radiolabeled agents targeting tumor-specific receptors
- **Purpose:** Assess safety and potential activity of novel therapies in GBM
- **Potential Benefit:** Contribute to ongoing research in glioblastoma under expert supervision

2 Cu64PSM0003 (Prostate Cancer)

- **Eligibility:** Individuals with newly diagnosed prostate cancer and Planned Prostatectomy
- **Focus:** Diagnostics approach for PSMA avid prostate cancer imaging
- **Purpose:** Investigate tumor imaging and targeted delivery of radiopharmaceuticals
- **Potential Benefit:** Contribute to ongoing research in prostate cancer under expert supervision

GET IN TOUCH

Refer a patient or contact us to learn more. Help advance cancer research and expand access to innovative diagnostic and therapeutic studies.



OUR CONTACT:



Ms. Susan Cork
Therapy Coordinator

713-204-1333

Dr. Ebrahim Delpassand

713-499-9733



www.exceldiagnostics.com



scork@exceldiagnostics.com

THERAPEUTIC TRIALS

1 Solid Tumor Clinical Trial (bladder/urothelial, triple-negative breast, colorectal, ovarian, and pancreatic cancers)

- **Eligibility:** Individuals with advanced or metastatic solid tumors
- **Focus:** Theragnostic approach combining imaging and targeted investigational radiotherapy
- **Purpose:** Investigate tumor imaging and targeted delivery of radiopharmaceuticals

2 Targeted Alpha Therapy, Neuroendocrine Tumors

- **Eligibility:** Individuals with advanced or metastatic NET tumors
- **Focus:** Theragnostic approach combining imaging and targeted investigational radiotherapy
- **Purpose:** Investigate tumor imaging and targeted delivery of radiopharmaceuticals This drug has received break through designation by FDA

3 Superscan Study (Prostate Cancer)

- **Eligibility:** Individuals with Progressive PSMA-Positive Prostate Cancer and Super Scan Bone Scan
- **Focus:** To assess the feasibility and safety of Lutetium-177-PSMA-617 (PLUVICTO) in mCRPC patients with a super scan on bone imaging
- **Purpose:** Investigate targeted delivery of radiopharmaceuticals
- **Potential Benefit:** Contribute to ongoing research in prostate cancer under expert supervision